Cysteine cathepsins and matrix metalloproteases are considered to play important roles in the development of arthritic diseases. Their accumulation in synovial fluid of primarily rheumatoid arthritis patients is also well documented. However, a detailed comparison between the protease levels and activities between rheumatoid arthritis samples and osteoarthritis samples has never been made. Here, we report that both cysteine cathepsins B and S and matrix metalloproteases-1, -3 and -13 are detected in patient synovial fluid samples with significantly higher levels detected in rheumatoid arthritis patients. Among the proteases, cathepsin S was found to be significantly elevated, consistent with its critical role in the immune response. These results suggest that cysteine cathepsins have a major role in inflammation at least in rheumatoid arthritis. In addition to proteases, interleukin-6 was detected at significant levels in most samples, suggesting that proinflammatory cytokines might be involved in the stimulation of expression of these proteases during inflammation.
Introduction
Rheumatoid arthritis (RA) and osteoarthritis (OA) are two major types of joint diseases in humans. RA is characterized by a chronic proliferative synovitis, which is caused by abnormal immunological reactions and exhibits hyperplasia of the synovial lining cells, inflammatory cell infiltration and angiogenesis. Moreover, synovitis was shown to play a key role in the destruction of articular cartilage and bone in RA (Kramer et al., 2003) . By contrast, OA is primarily a disease of cartilage that is characterized by degradation of the articular cartilage by proteases released from the articular chondrocytes. Inflammation in the adjacent synovial membrane is not prominent during early stages of the disease, although in the advanced stages of the disease synovitis might have been observed resulting in the production of proteases and modulation of the chondrocyte function (Wieland et al., 2005) .
The irreversible joint changes are mediated by the excessive protease activities resulting from the increased expression of various proteases, in particular cysteine cathepsins and metalloproteases, including matrix metalloproteases (MMPs) and aggrecanases, and/or altered equilibrium between these proteases and their endogenous inhibitors (Keyszer et al., 1998; Vasiljeva et al., 2007; Murphy and Nagase, 2008) . Both cysteine cathepsins and MMPs were shown to be involved in the degradation of extracellular matrix (ECM) components such as different types of collagens, proteoglycans, elastin, fibronectin and laminin (Maciewicz et al., 1987; Trabandt et al., 1991; Rengel et al., 2007; Murphy and Nagase, 2008) . However, an increasing number of expression profiling of synovial tissues and synovial fluids from patients with RA, and analyses of experimental arthritis, such as collagen-induced arthritis or the TNF-transgenic model, have shown important insights into the mechanisms of rheumatoid joint destruction with the pivotal role of cysteine cathepsins in the development of arthritis (Ibrahim et al., 2002; Schurigt et al., 2005) . Levels of cathepsins B and L have been found to be increased in the RA synovial membrane, particularly at the sites of bone and cartilage erosion. Cathepsin S, by contrast, is the major enzyme involved in the major histocompatibility complex (MHC) class II antigen processing and presentation (Riese et al., 1998; Turk et al., 2002b) . Moreover, cathepsin S knockout mice exhibited decreased susceptibility to collagen-induced arthritis and impaired processing of the invariant chain in both dendritic cells and B cells, consistent with the critical role of the enzyme in the immune response (Nakagawa et al., 1999) .
In addition to their ability to cleave almost all components of the ECM and thus contribute to the development and progression of different types of arthritis, MMPs were also found to process other proteases and protease inhibitors (Murphy and Nagase, 2008) . They are produced by chon- drocytes as well as synoviocytes, particularly when stimulated by interleukin-1 (IL-1) (Nakamura et al., 2006) . Among them, MMP-1, MMP-3 and MMP-13 have been most often linked with different arthritic diseases (Murphy and Nagase, 2008) . Moreover, owing to its preferential degradation of the type II collagen over the type I and the type III collagen, MMP-13 was suggested to be the most important enzyme for the degradation of collagen within cartilage (Cawston and Wilson, 2006) .
In addition to proteases, various proinflammatory cytokines, such as interleukin-1b (IL-1b), tumor necrosis factora (TNF-a) and interleukin-6 (IL-6), are key players in the progression and development of arthritic diseases. IL-1b and TNF-a are both expressed in synovial lining cells and have been reported to be present in the serum of patients with RA and OA. Furthermore, they were shown to induce expression and/or secretion of various matrix-degrading proteases, such as MMPs and cysteine cathepsins (Feldmann et al., 1996; Goldring and Goldring, 2004; Shi et al., 2004) .
Despite the clear role of selected proteases and proinflammatory cytokines in both RA and OA, little or no comparison has been made between the two diseases. To address this question, we have focused on the levels and activities of several cysteine cathepsins and MMPs in synovial fluid samples. Proteases have been detected in all samples with significantly higher levels and activities detected in patients with RA when compared with patients with OA, suggesting that proteases can play important roles in different types of arthritis and that they are suitable markers and/or therapeutic drug targets in these diseases.
Results

Clinical characteristics of the patients
Clinical characteristics of the patients with RA and OA are shown in Table 1 . The majority of patients with either disease were females. The mean age of the representative group of patients with RA was 56.12"9.60 years and 57.71" 17.33 years for patients with OA. All patients were in the late stage of disease progression and most of them were receiving different treatments at the time of sampling.
Proteinase activity in synovial fluid samples
As proteolytic activities have been previously found in the synovial fluids of RA patients, in the initial set of experiments the activities of selected cysteine cathepsins (B, L and S) and MMPs (MMP-1, MMP-3 and MMP-13), which had previously been shown to be involved in the development and/or progression of arthritic diseases, were determined in the synovial fluid samples from patients with RA or OA (Figures 1 and 2 ). All synovial fluid samples efficiently hydrolyzed Z-Phe-Arg-AMC (for abbreviations used in substrate names see the Materials and methods section), which is a general substrate for all cysteine cathepsins, suggesting that active cysteine cathepsins were present in the samples. To distinguish between the activities of different cathepsins, two more selective substrates were used: Bz-Phe-Val-Arg-AMC, which is a considerably more selective cathepsin S substrate, was hydrolyzed with much the same efficiency as Z-Phe-Arg-AMC, suggesting that most of the activity could be predominantly attributed to cathepsin S, and not to cathepsins B or L. The latter two enzyme activities were confirmed by the measurements of Z-Arg-Arg-AMC hydrolysis, characteristic for cathepsin B activity, which was very low in comparison with the hydrolysis of the other two substrates. However, although the patterns were the same in both RA and OA samples, significantly higher (p-0.05 for all fluorogenic substrates) activities of cysteine cathepsins were detected in samples from RA patients than from OA patients. Moreover, cathepsin activities were for an order of magnitude higher in the sample of one patient who refused therapy (not shown), although this was not statistically significant. MMP activity was monitored fluorometrically in synovial fluid samples of patients with RA or OA (shown as box and whiskers plot; white for RA patients, gray for OA patients). MMP-3-like activity was measured using the MMP-3 selective fluorogenic substrate MCAArg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH 2 , whereas MMP-13-like activity was measured by the MMP-13 selective fluorogenic substrate MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH 2 . The box represents data from the 25th percentile to the 75th percentile, with a horizontal line showing the median. The whiskers indicate the range of data. **p-0.01: statistical significance of MMP activity between RA and OA group. Other experimental details are described in the materials and methods section.
Next, we measured the activities of selected MMPs, namely MMP-1, MMP-3 and MMP-13, which have been shown to have a major role in ECM degradation. We found significantly (p-0.01) higher levels of MMP-3 and MMP-13 activities in RA patients when compared with OA patients. In contrast to the dramatically increased activities of cysteine cathepsins in the sample of the RA patient without treatment, the activities of MMPs in the same sample were comparable to the other samples. When the activity profiles of MMP-3 and MMP-13 were compared, no significant differences were observed (Figure 2 ), suggesting that they can equally contribute to ECM degradation during disease development. Surprisingly, no MMP-1 activity was observed in the synovial fluid samples under our experimental conditions.
Expression levels of selected cysteine cathepsins, cystatin C and MMPs in synovial fluid samples
Having found that several proteases were present in the samples, our next aim was to evaluate the amounts of these proteases in the samples by Western blot analysis. Major focus was on cathepsin S and MMP-3, for which the highest activities were observed. In addition, we also wanted to evaluate the levels of cathepsin B and MMP-1, which were previously reported to be present in synovial fluid (Hashimoto et al., 2001; Tchetverikov et al., 2005) , as well as the level of cystatin C, the major extracellular cathepsin inhibitor (Turk et al., 2002a) . When the samples were probed for cathepsin S, only a single band of approximately 28 kDa was observed in all samples, corresponding to mature cathepsin S ( Figure 3A) . However, more cathepsin S was observed in RA samples compared with OA, in agreement with the higher activities of cathepsin S measured in RA samples. Very interesting results were observed for cathepsin B. Although a strong signal corresponding to procathepsin B (45 kDa; Figure 3B ) was detected in the RA samples, only a faint band corresponding to the heavy chain of the mature cathepsin B (26 kDa; Figure 3B ) was observed in the same samples. In contrast, virtually no signal corresponding to either pro or the mature cathepsin B was detected in OA samples ( Figure 3B ). This is consistent with the low activity of cathepsin B observed in the RA samples and essentially no activity detected in the OA samples. As cathepsin activities could also be affected by the extracellular endogenous inhibitors, the synovial fluid samples were also probed for cystatin C, the major extracellular inhibitor of the cathepsins. All samples were cystatin C-positive, but the levels did not differ markedly between the RA and the OA patients ( Figure  3C ).
As the highest activity among MMPs was observed for MMP-3, we also expected to determine relatively high levels of the MMP-3 protein, at least in the RA samples. However, whereas a significant amount of pro-MMP-3 (approximately 56 kDa) form was detected in all patients ( Figure 4B ), surprisingly no mature form of the enzyme was observed in any of the samples. Despite the fact that no MMP-1 activity was detected, a strong signal corresponding to pro-MMP-1 (approximately 54 kDa; Figure 4A ) was observed in the RA patients and the signal was slightly less intense in the OA patients. The weaker signal at approximately 27 kDa in both groups of patients is a degradation product of MMP-1.
Measurement of cathepsin S and cytokine concentrations in synovial fluid samples
To quantify the amount of cathepsin S, which is the major proinflammatory cysteine cathepsin, and of selected proinflammatory cytokines in synovial fluids of the patients, different ELISA assays were performed. All data are summarized in Table 2 . The cathepsin S protein was detected in all patients with no significant differences (ps0.41) observed between the two diseases. An average concentration of 64.7 ng/ml of cathepsin S was found in the RA patients, and 43.8 ng/ml in the OA patients. IL-6 was also detected in all samples with significantly higher concentrations in the RA patients (p-0.01). An average concentration of IL-6 in patients with RA was 16.7 ng/ml, and in patients with OA 2.0 ng/ml. In contrast, IL-1b, a major proinflammatory cytokine, was detected in a single synovial fluid sample (23.3 ng/ ml) from the RA patient without therapy. Finally, detectable levels of another potent proinflammatory cytokine, TNF-a, were observed in four RA patients only with the average concentration of 27.6 pg/ml. The low number of TNF-apositive samples precluded any further statistical analyses.
Discussion
Progressive joint damage, mediated by excessive protease activities, is one of the most important predictors of the longterm outcome in RA and OA. Therefore, the proteases involved are suitable diagnostic markers for RA and OA and have also been validated as suitable drug targets for both diseases (Keyszer et al., 1998; Turk, 2006; Vasiljeva et al., 2007; Murphy and Nagase, 2008) . As prolonged synovitis is known to result in an excessive production of synovial fluid, the latter represents a rich source of proteases secreted from synovial lining cells or infiltrated inflammatory cells. In this study, cysteine cathepsins B and S and MMP-1, MMP-3 and MMP-13 were found to be differentially expressed and/or exhibited different activities in the synovial fluid samples of the late-stage patients with RA or OA. Higher expression levels and activities of all proteases tested were consistently observed in RA patients compared with OA patients. This could be linked with the primarily inflammatory nature of RA, which is crucial for disease progression, whereas it seems to be of lesser importance in OA.
As cysteine cathepsins, in particular cathepsin S, are known as critical mediators of the MHC class II-mediated immune response, which plays a major role in RA, their high activities are in agreement with this model (Nakagawa et al., 1999) . Anti-inflammatory therapies are thus expected to at partially dampen protease activities and expression levels at least in RA. In agreement with this concept, the single RA patient who refused to receive any treatment had largely increased cysteine cathepsin levels and activities (approximately 10-fold), when compared with the other RA patients who received various anti-inflammatory therapies to ease symptoms (Table 1) . This pattern was not observed for the activities of MMPs, although they take part in the generation of inflammation. Furthermore, our data are consistent with the important role of cysteine cathepsins in the generation of the inflammatory response. In contrast, in the group of OA patients the protease activities or levels were not significantly altered by therapy, further supporting the lesser importance of inflammation for the progression of OA. The important role of cysteine cathepsins in OA and RA has been further supported by a study in a mouse model of experimental inflammatory arthritis, where selective cysteine cathepsin inhibitors (peptidyl fluoromethyl ketones) decreased the severity of the disease (Esser et al., 1994) . Consistent with this and the previous results on expression profiles of the proteases in a mouse model of collageninduced arthritis (Schurigt et al., 2005) , cathepsin S was, based on activity data and expression levels, found to be the most prominent among the cysteine cathepsins in synovial fluid samples. Furthermore, cathepsin S knockout mice revealed a decrease in their susceptibility to collagen-induced arthritis and impaired invariant chain processing both in dendritic cells and B cells (Nakagawa et al., 1999) . This suggests that cathepsin S is mediating antigen presentation in different immune cells and is the driving factor in maintaining the inflammatory nature of RA. This is further supported by the finding that several gold derivative disease modifying antirheumatic drugs (DMARDs), which have been in clinics for a long time, efficiently inhibited cathep-sins S and K in vitro and in cells (Weidauer et al., 2007) . Although cathepsin B was also present in the synovial fluids of primarily RA patients, it was only found in the latent zymogen form, thereby suggesting being of lesser importance. Such latent procathepsin B forms have been found previously in human chondrocytes cultured from OA patients (Berardi et al., 2001) , where they were suggested to be capable of further autoactivation in a proper milieu (Mort and Recklies, 1986; Rozman et al., 1999; Caglič et al., 2007) . However, no active cathepsin B has been found in the samples of either RA or OA patients. Although this is in apparent contrast with some previous results on synovial fluid samples of patients with RA (Lenarčič et al., 1988; Gabrijelčič et al., 1990; Hashimoto et al., 2001) , these data are consistent with the activity data showing almost no activity on the cathepsin B substrate Z-Arg-Arg-AMC. Nevertheless, owing to the possibility that such latent precursor forms could be activated, they represent a permanent threat for the system, particularly as cathepsin B has been found to activate MMP precursors such as procollagenase and prostromelysin and could thus accelerate the proteolytic events contributing to the progression of the disease (Cunnane et al., 1999) . Although cystatin C, the major extracellular endogenous cysteine cathepsin inhibitor, has been found in samples of both RA and OA patients, its active role could not have been confirmed as significant cathepsin activity was detected in all samples.
In addition to cysteine cathepsins, levels of the three major MMPs linked with inflammatory processes in OA and RA, MMP-1, MMP-3 and MMP-13, were also found to be increased in the samples. MMP-3 activity levels in synovial fluid samples were found to be considerably higher in patients with RA than in patients with OA, in agreement with MMP-3 knockout mice studies, which suggest that MMP-3 is an important activator of other MMPs, particularly procollagenases in the cartilage and that the absence of MMP-3 significantly reduces tissue degradation in the immunemediated complex model of arthritis and in antigen-induced arthritis (van Meurs et al., 1999a,b) . Although we did not detect proteolytic activity of MMP-1, the protein was present in synovial fluid samples, consistent with its important role in arthritic diseases (Cunnane et al., 1999) . The increased activity of the third major MMP, MMP-13, also supports previous studies in human OA (Mitchell et al., 1996) and RA (Lindy et al., 1997) , where MMP-13 was reported to be expressed by both chondrocytes and synoviocytes. These data collectively demonstrate that MMPs are, in addition to cysteine cathepsins, important factors contributing to the arthritic disease progression, in agreement with previous evidence.
The most likely explanation for the increased protease levels in synovial fluids samples of RA patients compared with OA patients is their transcriptional regulation by the proinflammatory cytokines as suggested earlier (Shi et al., 2004) . Moreover, proinflammatory cytokines such as IL-1b, IL-6 and TNF-a, which are preferentially upregulated in RA, have been identified as key players in rheumatoid inflammation and destruction of ECM in RA and OA (Feldmann et al., 1996; Goldring and Goldring, 2004) . A plausible explanation for the detection of IL-6 only, but not IL-1b and TNF-a, at significant levels in all patients, is that all samples were withdrawn at a late stage of disease progression, whereas IL-1b and TNF-a are known to be involved in the initiation of the immune response thereby being considered as early stage cytokines (Kagari et al., 2002) . Moreover, the statistically significant almost 10-fold higher levels of IL-6 in RA compared with OA are consistent with the primarily inflammatory nature of RA. The major importance of the proinflammatory cytokines for RA progression is well documented and blockade of TNF-a and IL-1b, preventing their binding to the recepor(s) by DMARDs is one of the major approaches currently used in anti-RA therapy (Smolen and Steiner, 2003) , thereby supporting our results.
In conclusion, synovial fluids from RA and OA patients showed pronounced differences in protease activities and protein levels, suggesting that severe inflammation primarily accompanies RA, but not OA. In particular, cathepsin S was significantly upregulated, consistent with its crucial role in MHC class II-mediated immune response. Cathepsin S and MMP-3 and -13, together with IL-6, can therefore be considered as suitable markers for RA and OA, whereas selectively blocking cathepsin S is also likely to be beneficial for diminishing the immune response in RA in humans.
Materials and methods
Reagents and proteins
Abbreviations used in peptides: Abu (2-aminobutyric acid); Abz (aminobenzoic acid); AMC w7-(4-methyl)coumarylamidex; Bz (benzoyl); Cha (D-cyclohexylalanine); Cys(Me) (cysteine methyl ester); Dpa w(2,4-dinitrophenyl)-L-2,3-diaminopropionylx; Dnp (2,4-dinitrophenol); MCA (7-methoxy-coumarin-4-yl)acetyl; Me (methyl); N-Me-Abz (N-methylanthranilic acid); Nva (norvaline); Z (benzyloxycarbonyl).
Synthetic peptidic substrates for cysteine cathepsins Z-Arg-Arg-AMC, Z-Phe-Arg-AMC, Bz-Phe-Val-Arg-AMC and MCA-ArgPro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH 2 (substrate for MMP-3) were purchased from Bachem (Bubendorf, Switzerland); MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH 2 (substrate for MMP-13) and DNP-Pro-Cha-Abu-Cys(Me)-His-Ala-Lys(N-Me-Abz)-NH 2 (substrate for MMP-1) were obtained from Calbiochem (Darmstadt, Germany). The general cysteine inhibitor E-64 was obtained from the Peptide Institute (Osaka, Japan). Mouse monoclonal antibodies against MMP-1 (ab38923) and against MMP-3 (ab38907) were from Abcam (Cambridge, UK). Mouse monoclonal anti-cathepsin B (3E1), rabbit polyclonal anti-cathepsin S and rabbit polyclonal anti-cystatin C antibodies were prepared in our laboratory. All horseradish peroxidase-conjugated secondary antibodies were from Jackson ImmunoResearch Europe (Suffolk, UK); ECL WB detection reagent was purchased from GE Healthcare Europe GmbH (Munich, Germany). Commercially available ELISA assays for cathepsin S and TNF-a were obtained from R&D Systems (Wiesbaden-Nordenstadt, Germany), and IL-1b and IL-6 were from Pierce Biotechnology (Rockford, IL, USA). Recombinant cathepsin B (Kuhelj et al., 1995) , cathepsin S (Mihelič et al., 2008) , cystatin C (Cimerman et al., 1999) , MMP-1 (Chung et al., 2000) and MMP-3 (Suzuki et al., 1998) were prepared according to published protocols.
Patient characteristics
Synovial fluid samples were obtained from knee joints of patients with either RA or OA. A total of 16 samples of synovial fluid were collected, including 9 samples from patients with RA and 7 samples from patients with OA. Synovial fluids were immediately centrifuged (300 g, 15 min, 48C) to remove the cells and the supernatants were then aliquoted and stored at -808C until further use. Patient characteristics, inflammatory parameters from the blood samples obtained and the type(s) of therapy at the time of sampling are shown in Table 1 . Patients with RA, with the exception of patient number 6, who refused to receive any therapy, were receiving one or more disease modifying anti-rheumatic drugs (DMARDs), such as methotrexate, sulfasalazine and resochine, three of them in combination with glucocorticoid methylprednisolone. A single RA patient was receiving only TNF-a inhibitor infliximab. By contrast, patients with OA were receiving either non-steroidal anti-inflammatory drugs, such as meloxicam or diclofenac, or analgesic tramadol hydrochloride, whereas no therapy data were available for three patients.
Quantitative determination of cathepsin S and cytokine concentrations in synovial fluid
Protein concentrations of cathepsin S, IL-1b, TNF-a and IL-6 were determined using the commercially available ELISA assays according to the manufacturers' instructions with cut-off points of 15.6 pg/ ml (for cathepsin S and TNF-a) and 10.24 pg/ml (for IL-1b and IL-6).
Gel electrophoresis and Western blot analysis for cathepsins B and S, cystatin C and matrix metalloproteinases -1 and -3
Synovial fluids were diluted 10 times in dH 2 O to a final volume of 100 ml and SDS loading buffer was added. Aliquots of 20 ml were separated on 12.5% or 15% SDS-PAGE gels and transferred onto a nitrocellulose membrane. Membranes were blocked in phosphate buffered saline (PBS), 0.1% Tween 20, 5% (w/v) dry milk for 1 h at room temperature and then incubated with mouse monoclonal anti-human cathepsin B antibody (1:1000), rabbit polyclonal antihuman cathepsin S antibody (1:2000), rabbit polyclonal anti-human cystatin C (1:800), mouse monoclonal anti-human MMP-1 antibody (1:6000) or mouse monoclonal anti-human MMP-3 antibody (1:3000) in PBS, 0.1% Tween 20, 5% (w/v) dry milk at 48C overnight. Membranes were then incubated with the goat anti-mouse or the goat anti-rabbit IgG-peroxidase conjugate (1:5000) in PBS, 0.1% Tween 20, 5% (w/v) dry milk for 1 h at room temperature. Proteins were visualized using ECL WB detection reagent (GE Healthcare) according to the manufacturer's specifications.
Protease activity assays
Different AMC-derived fluorogenic substrates were used to measure cysteine cathepsin activities in synovial fluids. Synovial fluids (300 ml) were diluted in 100 mM sodium phosphate buffer, pH 6, containing 3 mM EDTA, 5 mM dithiothreitol and 0.1% (w/v) polyethylene glycol 6000 to a final volume of 1 ml. General cysteine cathepsin activity (B, K, L and S) was measured using Z-Phe-Arg-AMC w20 mM; k cat /K m (CatB)s1.6=10 ) and MMP-13-like activity using MCA-Pro-ChaGly-Nva-His-Ala-Dpa-NH 2 (l exc s325 nm, l em s395 nm; k cat / K m s1.09=10 6 s -1 M -1 ).
Statistical analysis
Results are given as average values. The non-parametric MannWhitney U-test was used to compare the differences between the two independent groups using SPSS 10.0 software. A p-value -0.05 was considered statistically significant.
